PhRMA press release on USTR Special 301, expresses disappointment over language for India, Canada
Below is the PhRMA press release on the Special 301 Report.
Key points in the PhRMA release:
* PhRMA “dismayed that USTR did not grant an out-of-cycle review for India.” PhRMA claims that India decisions involving German owned Bayer and Swiss owned Novartis “disproportionately impacted U.S. biopharmaceutical companies.” (Perhaps PhRMA could have said, companies that have ownership claims on the US government).